CN109395099B - 一种提高结核菌素bcg-ppd皮试诊断试剂稳定性的方法 - Google Patents
一种提高结核菌素bcg-ppd皮试诊断试剂稳定性的方法 Download PDFInfo
- Publication number
- CN109395099B CN109395099B CN201811529499.XA CN201811529499A CN109395099B CN 109395099 B CN109395099 B CN 109395099B CN 201811529499 A CN201811529499 A CN 201811529499A CN 109395099 B CN109395099 B CN 109395099B
- Authority
- CN
- China
- Prior art keywords
- ppd
- bcg
- culture
- tween
- volume
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 70
- 229960001005 tuberculin Drugs 0.000 title claims abstract description 33
- 238000012360 testing method Methods 0.000 title claims abstract description 32
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 26
- 239000011550 stock solution Substances 0.000 claims abstract description 38
- 229920000136 polysorbate Polymers 0.000 claims abstract description 31
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 239000006185 dispersion Substances 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 32
- 239000001963 growth medium Substances 0.000 claims description 29
- 238000001556 precipitation Methods 0.000 claims description 19
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 16
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 claims description 15
- 241000894006 Bacteria Species 0.000 claims description 15
- 239000012528 membrane Substances 0.000 claims description 15
- 230000001954 sterilising effect Effects 0.000 claims description 15
- 238000000502 dialysis Methods 0.000 claims description 13
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 12
- 229920000053 polysorbate 80 Polymers 0.000 claims description 12
- 230000002779 inactivation Effects 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 10
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 9
- 244000061456 Solanum tuberosum Species 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000003068 static effect Effects 0.000 claims description 8
- 241000233866 Fungi Species 0.000 claims description 6
- 238000011146 sterile filtration Methods 0.000 claims description 6
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 230000037303 wrinkles Effects 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 241000193764 Brevibacillus brevis Species 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 abstract description 36
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract description 8
- 238000001514 detection method Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract 1
- 229960002109 tuberculosis vaccine Drugs 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
- 239000000047 product Substances 0.000 description 16
- 238000010790 dilution Methods 0.000 description 15
- 239000012895 dilution Substances 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 229960004319 trichloroacetic acid Drugs 0.000 description 13
- 239000000306 component Substances 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000003085 diluting agent Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 235000011130 ammonium sulphate Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 208000015355 drug-resistant tuberculosis Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 241000186146 Brevibacterium Species 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 108010046334 Urease Proteins 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 2
- 229910001626 barium chloride Inorganic materials 0.000 description 2
- 238000005842 biochemical reaction Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 2
- 229940107698 malachite green Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 206010060976 Bacillus infection Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010022075 Injection site induration Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000036347 rifampicin-resistant tuberculosis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811529499.XA CN109395099B (zh) | 2018-12-13 | 2018-12-13 | 一种提高结核菌素bcg-ppd皮试诊断试剂稳定性的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811529499.XA CN109395099B (zh) | 2018-12-13 | 2018-12-13 | 一种提高结核菌素bcg-ppd皮试诊断试剂稳定性的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109395099A CN109395099A (zh) | 2019-03-01 |
CN109395099B true CN109395099B (zh) | 2020-02-21 |
Family
ID=65459205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811529499.XA Active CN109395099B (zh) | 2018-12-13 | 2018-12-13 | 一种提高结核菌素bcg-ppd皮试诊断试剂稳定性的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109395099B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113444671A (zh) * | 2021-08-04 | 2021-09-28 | 成都可恩生物科技有限公司 | 一种可替代苏通马铃薯培养基的卡介菌菌种传代培养方法 |
CN114748615A (zh) * | 2022-04-29 | 2022-07-15 | 成都安永鼎业生物技术有限公司 | 一种治疗用重组卡介苗的冻干制剂及其制备方法和用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101732732A (zh) * | 2009-12-17 | 2010-06-16 | 中国兽医药品监察所 | 牛型结核菌素标准物质及其制备方法 |
CN103993065A (zh) * | 2014-05-07 | 2014-08-20 | 济宁医学院 | 一种结核分枝杆菌双相快速鉴别培养基及其应用 |
CN104237508A (zh) * | 2013-06-19 | 2014-12-24 | 华中农业大学 | 一种结核分枝杆菌的检测试剂盒及应用 |
-
2018
- 2018-12-13 CN CN201811529499.XA patent/CN109395099B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101732732A (zh) * | 2009-12-17 | 2010-06-16 | 中国兽医药品监察所 | 牛型结核菌素标准物质及其制备方法 |
CN104237508A (zh) * | 2013-06-19 | 2014-12-24 | 华中农业大学 | 一种结核分枝杆菌的检测试剂盒及应用 |
CN103993065A (zh) * | 2014-05-07 | 2014-08-20 | 济宁医学院 | 一种结核分枝杆菌双相快速鉴别培养基及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN109395099A (zh) | 2019-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Felix | A new type of typhoid and paratyphoid vaccine | |
CN101402944B (zh) | 一种ev-71病毒毒种、人用灭活疫苗及其制备方法 | |
Cecil et al. | Bacteriology of the blood and joints in rheumatic fever | |
CN106344920A (zh) | 一种疫苗用佐剂及其应用 | |
CN111500482B (zh) | 一种羊a型产气荚膜梭菌菌株及其灭活疫苗和疫苗制备方法 | |
CN109395099B (zh) | 一种提高结核菌素bcg-ppd皮试诊断试剂稳定性的方法 | |
CN108392628A (zh) | 一种猪支原体肺炎灭活疫苗及其制备方法 | |
CN109182167B (zh) | 一种高效价结核菌素皮试诊断试剂(ppd)生产工艺 | |
CN104258386B (zh) | 一种水貂病毒性肠炎灭活疫苗-犬瘟热活疫苗组合 | |
CN102348466B (zh) | 西尼罗病毒疫苗 | |
CN103127497B (zh) | 猪圆环病毒2型、肺炎支原体二联灭活疫苗及其制备方法 | |
CN108949700B (zh) | 一种山羊副流感病毒3型js14-2株及其应用 | |
CN109745555B (zh) | 一种猪肺炎支原体与副猪嗜血杆菌二联灭活疫苗及其应用 | |
Hilleman et al. | Adenovirus (ri-apc-ard) vaccine for prevention of acute respiratory illness: 1. vaccine development | |
CN104069489B (zh) | 鸡新城疫和传染性法氏囊二联灭活疫苗及其制备方法 | |
CN106834168A (zh) | 一种猪链球菌2型弱毒株及其应用 | |
CN113957007B (zh) | 一种鸡滑液囊支原体灭活疫苗 | |
CN1843507B (zh) | 一种人用腮腺炎病毒组份疫苗及其制备方法和应用 | |
CN112899329B (zh) | 一种结核菌素纯蛋白衍生物的生产方法 | |
CN102805862A (zh) | 一种vero细胞培养新布尼亚病毒纯化灭活疫苗的制备方法 | |
CN106929480A (zh) | 猪繁殖与呼吸综合征病毒株及其应用 | |
CN112717128B (zh) | 一种预防手足口病的联合疫苗及其制备方法和应用 | |
CN1331531C (zh) | 一种治疗慢性胃炎的药物 | |
CN110124022B (zh) | 一种猪肺炎支原体与副猪嗜血杆菌、猪链球菌、胸膜肺炎放线杆菌四联灭活疫苗及其应用 | |
CN102805863B (zh) | 一种人二倍体细胞培养新布尼亚病毒纯化灭活疫苗的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 101407 No.17, Yanqi North 3rd Street, Yanqi Economic Development Zone, Huairou District, Beijing Patentee after: Beijing Xiangrui Biological Products Co.,Ltd. Address before: 101407 No.17, Yanqi North 3rd Street, Yanqi Economic Development Zone, Huairou District, Beijing Patentee before: BEIJING SANROAD BIOLOGICAL PRODUCTS CO.,LTD. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 101407 No.17, Yanqi North 3rd Street, Yanqi Economic Development Zone, Huairou District, Beijing Patentee after: Beijing Xiansheng Xiangrui Biological Products Co.,Ltd. Address before: 101407 No.17, Yanqi North 3rd Street, Yanqi Economic Development Zone, Huairou District, Beijing Patentee before: Beijing Xiangrui Biological Products Co.,Ltd. |